GuideNeurology

PML risk with natalizumab in multiple sclerosis

Factors that stratify the risk of progressive multifocal leukoencephalopathy (PML) in MS patients treated with natalizumab.

Updated 3 November 2026

When to use it

Before starting natalizumab and at each benefit-risk reassessment (at least yearly).

Warning

The original tool's risk table is outdated. Figures here are indicative; use the current product information for individual decisions.

What it is

PML is an opportunistic CNS infection by JC virus that can occur with natalizumab. Risk is not uniform: it is stratified with simple data available in clinic. Published risk tables come from the manufacturer and observational cohorts and have been updated over time.

Keep reading in the app

  • Risk factors
  • Published figures (Ho 2017)
  • How it is used in practice
  • Limitations

Practical tip

The three classic factors are: positive anti-JCV antibodies, prior immunosuppressants and treatment duration (especially beyond 24 months).

3 more practical tips in the app.

Reference

Official source: Tysabri: official EMA information

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top